Table 1.
Key traditional Chinese medicine interventions, their primary targets, and level of evidence in inflammatory bowel disease
|
Key TCM intervention
|
Primary targets/pathways
|
Level of evidence
|
| Xianglian pill | TLR4/MyD88/NF-κB | B |
| Abelmoschus manihot extract | IL-10 | B |
| Glycyrrhiza uralensis aqueous extract | NOD2/RIP2/NF-κB | B |
| Luteolin | AMPK/PPAR-γ | B, C |
| Shaoyao decoction | PPAR/NF-κB | B |
| Phillygenin | TLR4/Src/MAPK, NF-κB | B |
| Si-Ni-San | Gut microbiota (Akkermansia muciniphila) | B |
| Ginsenoside-derived exosome-like nanoparticles | NF-κB | C |
| Gegen Qinlian decoction | AHR/ferroptosis pathway | B |
| Astragaloside IV | PI3K/AKT | B, C |
| Baitouweng decoction | AMPK/mTOR | B |
| Schisandrin | SGK1/NLRP3 | B |
| Qingchang Wenzhong decoction | Guanylyl cyclase-C/HIF-α | B, C (patient cells) |
| Saussurea costus | Gut microbiota/tight junctions | B |
| Citropten | NF-κB, JAK/STAT3 | B |
TCM: Traditional Chinese medicine; TLR4: Toll-like receptor 4; MyD88: Myeloid differentiation primary response 88; NF-κB: Nuclear factor-kappa B; IL: Interleukin; NOD2: Nucleotide-binding oligomerization domain-containing protein 2; RIP2: Receptor-interacting serine-threonine kinase 2; AMPK: Adenosine monophosphate-activated protein kinase; PPAR-γ: Peroxisome proliferator-activated receptor-γ; MAPK: Mitogen-activated protein kinase; AHR: Aryl hydrocarbon receptor; PI3K: Phosphatidylinositol 3-kinase; AKT: Protein kinase B; mTOR: Mammalian target of rapamycin; SGK1: Serum/glucocorticoid regulated kinase 1; NLRP3: Nucleotide-binding oligomerisation domain-like receptor family pyrin domain containing 3; HIF-α: Hypoxia inducible factor-α; JAK: Janus kinase; STAT3: Signal transducer and activator of transcription 3.